Long-term results of aortic valve replacement with xenogenic pericardial stentless prosthesis BioLAB KB/A

Abstract

Aim . To evaluate long-term results of using xenogenic pericardial stentless prosthesis BioLAB KB/A. Material and methods . From 2007 to 2014, 57 xenogenic pericardial stentless prostheses BioLAB KB/A were implanted. The mean age of operated patients was 70±4 (49-80 years of age); 6 patients were younger than 65 years old. The mean follow-up period was 8 years (4-11 years). The mean age of patients at the time of examination was 79 (70-89) years. Results . Five- and ten-year survival rates were 73,82±7,99% and 51,01±11,23%, respectively. Four patients underwent long-term reoperation due to bioprosthetic valve dysfunction. Freedom from reoperation associated with infective endocarditis after a year was 95,1±2,4%, three years — 92,65±4,1%, five years — 89,1±5,2%, and seven years — 89,1±5,2%. Freedom from prosthetic valve dysfunction due to structural degeneration was 9,58±1,83 years. Conclusion. We consider it possible to use the xenogenic pericardial stentless prostheses BioLAB KB/A for aortic valve replacement in elderly patients, especially with a narrow aortic root. However, using a technically more complex technique for a larger geometric opening is not justified. Significant regurgitation at 7 years after surgery requires considering reoperation, but already in older patients and with a number of comorbidities.